Find Reports
Select Report Type
Reimbursement Review
Displaying 1051 - 1075 of 1258
Please scroll or swipe to the right to view the full content.
| Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|
| Viibryd | vilazodone | Depression, Major depressive disorder | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0006-000 | |||
| Imbruvica | ibrutinib | Chronic graft versus host disease | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0009-000 | |||
| Revolade | eltrombopag | Severe aplastic anemia | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0007-000 | |||
| Symdeko | tezacaftor/ivacaftor | Cystic fibrosis, F508del mutation(s) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0008-000 | |||
| Zytiga (Resubmission) | Abiraterone | Prostate Cancer Resubmission | Withdrawn | PC0201-000 | ||||
| TBD | Entrectinib | Withdrawn | PC0157-000 | |||||
| Atriance | Nelarabine | Cancelled | PC0170-000 | |||||
| TBC | ravulizumab | Paroxysmal nocturnal hemoglobinuria. | Withdrawn | SR0623-000 | ||||
| Demylocan | decitabine | Myelodysplastic Syndromes | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0001-000 | |||
| Imbruvica | ibrutinib | Leukemia | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0005-000 | |||
| Oncaspar | pegaspargase | Adult Acute Lymphocytic Leukemia (ALL) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0002-000 | |||
| Zevalin | iIbritumomab tiuxetan | Non-Hodgkin’s Lymphoma (NHL) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0003-000 | |||
| Tecentriq | Atezolizumab | Withdrawn | PC0171-000 | |||||
| TBC | etonogestrel | Prevention of pregnancy | Withdrawn | SR0629-000 | ||||
| TBC | filgotinib | Arthritis, Rheumatoid | Withdrawn | SR0656-000 | ||||
| Aduhelm | aducanumab | Alzheimer’s disease | Withdrawn | SR0705-000 | ||||
| Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Withdrawn | PC0271-000 | ||||
| Fabhalta | iptacopan | paroxysmal nocturnal hemoglobinuria (PNH) | Active | SR0851-000 | ||||
| Brukinsa | zanubrutinib | Relapsed or refractory follicular lymphoma | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0037-000 | |||
| Sunosi | solriamfetol | Excessive daytime sleepiness (narcolepsy) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0038-000 | |||
| Keytruda | pembrolizumab | Primary mediastinal B-cell lymphoma | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0034-000 | |||
| Lynparza | olaparib | Breast Cancer | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0013-000 | |||
| Firazyr | icatibant | Acute attacks of hereditary angioedema | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0014-000 | |||
| Zolinza | vorinostat | Cutaneous T-cell lymphoma | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0015-000 | |||
| Xofluza | baloxavir marboxil | Influenza | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0016-000 |
Health Technology Review
Displaying 576 - 589 of 589
Horizon Scan
Displaying 101 - 111 of 111
Projects in Progress
Displaying 26 - 40 of 40
View All Reports
Displaying 1051 - 1075 of 2093
Please scroll or swipe to the right to view the full content.